Meitheal Pharmaceuticals (Meitheal) is pleased to announce the official launch of Adenosine Injection, USP:
- 71288-207-21: Adenosine Injection, USP 60mg per 20mL (3mg per mL) SDV
- 71288-208-30: Adenosine Injection, USP 90mg per 30mL (3mg per mL) SDV
ABOUT ADENOSINE INJECTION, USP
Adenosine Injection, a pharmacological stress agent, is indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately.
The recommended adenosine injection dose is 0.14 mg/kg/min infused over six minutes (total dose of 0.84 mg/kg).
- Administer adenosine injection only as a continuous peripheral intravenous infusion
- Inject Thallium-201 at the midpoint of the adenosine injection infusion (i.e. after the first three minutes of adenosine injection)
- Thallium-201 is physically compatible with adenosine injection and may be injected directly into the adenosine injection infusion set.
- Inject Thallium-201 as close to the venous access as possible to prevent an inadvertent increase in the dose of adenosine injection (the contents of the intravenous tubing) being administered.
- Visually inspect adenosine injection for particulate matter and discoloration prior to administration. Do not administer adenosine injection if it contains particulate matter or is discolored.
There are no data on the safety or efficacy of alternative adenosine infusion protocols. The safety and efficacy of adenosine injection administered by the intracoronary route have not been established.
For full prescribing information, please click on the following link.
Learn more about who we are and what we do at: www.meithealpharma.com.
